Merck faces the first trial due to lawsuits based on its osteoporosis drug Fosamax allegedly causing the death of jawbone tissue. The Fosamax plaintiffs claim Merck misrepresented the drug’s safety and failed to that it might impede blood flow to the jaw, causing jawbone-tissue death. This condition called osteonecrosis of the jaw, or ONJ can lead to partial removal in some patients. Jawbone tissue death is . Fosamax, available in pill or liquid form, is part of a group of medicines known as bisphosphonates. The only cases of jaw necrosis have been found in the drugs’ users and cancer patients receiving chemotherapy, according to Mahyar Etminan, a pharmacy expert for the patients. http://www.bloomberg.com/apps/news?pid=20601103&sid=aN.O.OLorMnc
Comments are closed.